Reinventing Vision Screening.

We are building the world’s most comprehensive, self-administered, ultra-portable ocular screening device—enabling rapid risk stratification of leading causes of blindness.
Self-administered
No space constraints
Immediate Results
Our Value Proposition

First in the world spatial
ETDRS Visual Acuity Test.

The only device in the world at the moment to support complete Early Treatment of Diabetic Retinopathy Study (ETDRS) Visual Acuity Chart in a Augmented Reality device.*

Self-administered &
Remote-Testing.

Designed for patient-led assessments, improving accessibility and convenience. Proven to increase testing capacity exponentially.

Significant Cost-savings
of 95.3% per test.

Proven to reduce ETDRS test costs by 95.3%, making vision screening care more affordable.**

Comprehensive.

Screens for cataracts, glaucoma, macular degeneration, and other leading causes of blindness in a single device.***

Leaders in vision care

We are the leaders for vision care screening.

Our goal is to transform global eye care by providing innovative, accessible, and cost-effective solutions that empower early detection and management of vision-threatening conditions.

Our Partners
How it works

White Paper

Building the world’s first Augmented Reality Vision Screening Device. (Coming Soon)
  • Glass, Moon Technologies Pte. Ltd.’s device is a Class A certified Medical Device as authorised by Health Science and Authority (HSA).

  • At present, the device is able to perform visual acuity tests (EDTRS) spatially, and the other upcoming ocular screening tests are in R&D.

  • Cost savings demonstrated are based on a projected case study at Tan Tock Seng Hospital Eye Clinic using 30 sets of Glasses to complete 400 tests daily (current testing capacity).

  • Preliminary trial done in collaboration with TTSH showed promising equivalence of a low mean difference between Glass M’s EDTRS Visual Acuity Test vs Manual EDTRS Chart ( mean difference ~ 0.2logMAR or 2 rows). Hardware iterations are in progress to improve mean difference to 0.1, exhibiting clinically insignificant differences between the 2 methods in 2024.